Moreover, conventional immunotherapies such as PD-1/PD-L1 inhibitors have demonstrated limited clinical benefit in OS, largely due to its inherent low tumor mutational burden (TMB), impaired antigen presentation, and profoundly immunosuppressive tumor microenvironment (TME), leading to objective response rates typically below 10% (4, 5). The gene discussed is CD274; the disease is neoplasm.